Publications by authors named "D F Warnock"
J Inherit Metab Dis
January 2025
Article Synopsis
- Pegunigalsidase alfa is a new enzyme replacement therapy for Fabry disease, showing a longer half-life and administered every 4 weeks instead of the typical 2-week schedule.
- The BRIGHT study involved 30 adult patients who switched from another ERT to pegunigalsidase alfa, revealing good safety results with mostly mild side effects and no new anti-drug antibodies.
- Although the treatment showed acceptable tolerance, more research is needed due to the small sample size, but it suggests that this 4-week regimen could be a viable new option for managing Fabry disease.
Article Synopsis
- * The Birmingham Orthopaedic Oncology Meeting in January 2024 gathered 300 experts from over 50 countries to reach global consensus on chondrosarcoma treatment and address challenges related to periprosthetic joint infection in cancer surgeries.
- * The meeting aimed to not only resolve current controversies but also to encourage collaboration among specialists for future research that could improve patient outcomes worldwide.
Article Synopsis
- Pegunigalsidase alfa is a new enzyme replacement therapy compared to agalsidase beta for treating Fabry disease, evaluated through the BALANCE trial.
- In the study, 77 adult patients were randomly assigned to receive either treatment every two weeks for two years, focusing on eGFR slope differences to measure effectiveness.
- Results showed that pegunigalsidase alfa was not inferior to agalsidase beta in terms of eGFR decline, with fewer adverse events and infusion reactions for the new treatment.
